$1.03
-0.09 (-8.04%)
Open$1.09
Previous Close$1.12
Day High$1.11
Day Low$1.01
52W High$2.86
52W Low$1.08
Volume—
Avg Volume3.84M
Market Cap199.89M
P/E Ratio—
EPS$-0.64
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+327.2% upside
Current
$1.03
$1.03
Target
$4.40
$4.40
$2.36
$4.40 avg
$4.89
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 116.39M | 123.33M | 94.21M |
| Net Income | 12.19M | 12.43M | 9.10M |
| Profit Margin | 10.5% | 10.1% | 9.7% |
| EBITDA | 16.58M | 20.40M | 14.08M |
| Free Cash Flow | 11.50M | 12.12M | 8.26M |
| Rev Growth | -3.2% | +20.3% | +7.0% |
| Debt/Equity | 0.59 | 0.58 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.55 | -0.16% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $456.60 | -1.24% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $169.42 | +1.10% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $531.97 | -1.08% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $951.08 | -0.14% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $159.73 | -3.22% | 7.7 | 20.98B |